GOALS OF WORK: Despite advances in allogeneic hematopoietic stem cell transplantation (HSCT), post-transplant complications are common, and patients' symptom experience has not been well documented. PURPOSE: To characterize the symptom experience of adult patients pre-transplantation and days 0, 30, and 100 after allogeneic HSCT. METHODS: Data from 76 participants enrolled in a prospective health-related quality of life (HRQL) study were used. Symptom occurrence, distress, and clusters were determined based on the 11 symptoms of the Symptom Distress Scale (SDS). RESULTS: Participants were on average 40 years old (SD +/- 13.5). The majority (54%) received reduced intensity conditioning. Prevalent symptoms included fatigue (68%) and worry (68%) at baseline, appetite change (88%) at day 0, and fatigue at days 30 (90%) and 100 (81%). Participants reported the following symptoms as severely distressing: worry (16%) [baseline], insomnia (32%) [day 0], appetite change (22%) [day 30], and fatigue (11%) [day 100]. The total SDS score was highest at day 0 (M = 26.6 +/- 7.6) when the highest number of symptoms were reported [median = 8 (1-11)]. Symptoms formed clusters comprised of fatigue, appearance change, and worry at baseline, and fatigue, insomnia, and bowel changes at days 0 and 30. Compared to those with low symptom distress, participants with moderate/severe symptom distress reported poorer HRQL. CONCLUSION: Allogeneic HSCT patients present for transplantation with low symptom distress yet experience multiple symptoms and high symptom distress after HSCT conditioning. Understanding the symptom experience of allogeneic HSCT patients can guide management strategies and improve HRQL.
GOALS OF WORK: Despite advances in allogeneic hematopoietic stem cell transplantation (HSCT), post-transplant complications are common, and patients' symptom experience has not been well documented. PURPOSE: To characterize the symptom experience of adult patients pre-transplantation and days 0, 30, and 100 after allogeneic HSCT. METHODS: Data from 76 participants enrolled in a prospective health-related quality of life (HRQL) study were used. Symptom occurrence, distress, and clusters were determined based on the 11 symptoms of the Symptom Distress Scale (SDS). RESULTS:Participants were on average 40 years old (SD +/- 13.5). The majority (54%) received reduced intensity conditioning. Prevalent symptoms included fatigue (68%) and worry (68%) at baseline, appetite change (88%) at day 0, and fatigue at days 30 (90%) and 100 (81%). Participants reported the following symptoms as severely distressing: worry (16%) [baseline], insomnia (32%) [day 0], appetite change (22%) [day 30], and fatigue (11%) [day 100]. The total SDS score was highest at day 0 (M = 26.6 +/- 7.6) when the highest number of symptoms were reported [median = 8 (1-11)]. Symptoms formed clusters comprised of fatigue, appearance change, and worry at baseline, and fatigue, insomnia, and bowel changes at days 0 and 30. Compared to those with low symptom distress, participants with moderate/severe symptom distress reported poorer HRQL. CONCLUSION: Allogeneic HSCT patients present for transplantation with low symptom distress yet experience multiple symptoms and high symptom distress after HSCT conditioning. Understanding the symptom experience of allogeneic HSCT patients can guide management strategies and improve HRQL.
Authors: M Díez-Campelo; J A Pérez-Simón; J R González-Porras; J M García-Cecilia; M Salinero; M D Caballero; M C Cañizo; E M Ocio; J F San Miguel Journal: Bone Marrow Transplant Date: 2004-10 Impact factor: 5.483
Authors: D Wu; D M Hockenberry; T A Brentnall; P H Baehr; R J Ponec; R Kuver; S P Tzung; J L Todaro; G B McDonald Journal: Transplantation Date: 1998-11-27 Impact factor: 4.939
Authors: M Kopp; H Schweigkofler; B Holzner; D Nachbaur; D Niederwieser; W W Fleischhacker; B Sperner-Unterweger Journal: Ann Hematol Date: 1998 Jul-Aug Impact factor: 3.673
Authors: Ashley Leak Bryant; Erin Coffman; Brett Phillips; Xianming Tan; Elizabeth Bullard; Rachel Hirschey; Joshua Bradley; Antonia V Bennett; Angela M Stover; Lixin Song; Thomas C Shea; William A Wood Journal: Support Care Cancer Date: 2019-06-20 Impact factor: 3.603
Authors: Marcia Grant; Liz Cooke; Anna Cathy Williams; Smita Bhatia; Leslie Popplewell; Gwen Uman; Stephen Forman Journal: Support Care Cancer Date: 2012-02-09 Impact factor: 3.603
Authors: Anna Barata; Brian D Gonzalez; Steven K Sutton; Brent J Small; Paul B Jacobsen; Teresa Field; Hugo Fernandez; Heather Sl Jim Journal: J Health Psychol Date: 2016-04-22
Authors: Alex J Fauer; Flora Hoodin; Leah Lalonde; Josh Errickson; Lyndsey Runaas; Tracey Churay; Sajjad Seyedsalehi; Casiana Warfield; Grant Chappell; Kristina Brookshire; Dima Chaar; Ji Youn Shin; Michelle Byrd; John Magenau; David A Hanauer; Sung Won Choi Journal: Support Care Cancer Date: 2018-09-20 Impact factor: 3.603
Authors: A M J Braamse; B van Meijel; O Visser; P C Huijgens; A T F Beekman; J Dekker Journal: Bone Marrow Transplant Date: 2013-10-07 Impact factor: 5.483
Authors: William A Wood; Allison M Deal; Amy Abernethy; Ethan Basch; Claudio Battaglini; Yoon Hie Kim; Julia Whitley; Charlotte Shatten; Jon Serody; Thomas Shea; Bryce B Reeve Journal: Biol Blood Marrow Transplant Date: 2012-12-16 Impact factor: 5.742
Authors: Timothy S Sannes; Teresa L Simoneau; Susan K Mikulich-Gilbertson; Crystal L Natvig; Benjamin W Brewer; Kristin Kilbourn; Mark L Laudenslager Journal: Support Care Cancer Date: 2018-10-24 Impact factor: 3.603